Literature DB >> 16107141

Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure.

Michael C Jaye1, John A Krawiec, Nino Campobasso, Angela Smallwood, Chunyan Qiu, Quinn Lu, John J Kerrigan, Maite De Los Frailes Alvaro, Bryan Laffitte, Wu-Schyong Liu, Joseph P Marino, Craig R Meyer, Jason A Nichols, Derek J Parks, Paloma Perez, Lea Sarov-Blat, Sheila D Seepersaud, Klaudia M Steplewski, Scott K Thompson, Ping Wang, Mike A Watson, Christine L Webb, David Haigh, Justin A Caravella, Colin H Macphee, Timothy M Willson, Jon L Collins.   

Abstract

Substituted 3-(phenylamino)-1H-pyrrole-2,5-diones were identified from a high throughput screen as inducers of human ATP binding cassette transporter A1 expression. Mechanism of action studies led to the identification of GSK3987 as an LXR ligand. GSK3987 recruits the steroid receptor coactivator-1 to human LXRalpha and LXRbeta with EC(50)s of 40 nM, profiles as an LXR agonist in functional assays, and activates LXR though a mechanism that is similar to first generation LXR agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107141     DOI: 10.1021/jm050532w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism.

Authors:  Yu Xue; Esther Chao; William J Zuercher; Timothy M Willson; Jon L Collins; Matthew R Redinbo
Journal:  Bioorg Med Chem       Date:  2006-12-20       Impact factor: 3.641

2.  Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR.

Authors:  Matthew D Krasowski; Ai Ni; Lee R Hagey; Sean Ekins
Journal:  Mol Cell Endocrinol       Date:  2010-07-06       Impact factor: 4.102

3.  Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators.

Authors:  Sayaka Nomura; Kaori Endo-Umeda; Atsushi Aoyama; Makoto Makishima; Yuichi Hashimoto; Minoru Ishikawa
Journal:  ACS Med Chem Lett       Date:  2015-07-13       Impact factor: 4.345

Review 4.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

5.  Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.

Authors:  Zhe Wang; A Dessa Sadovnick; Anthony L Traboulsee; Jay P Ross; Cecily Q Bernales; Mary Encarnacion; Irene M Yee; Madonna de Lemos; Talitha Greenwood; Joshua D Lee; Galen Wright; Colin J Ross; Si Zhang; Weihong Song; Carles Vilariño-Güell
Journal:  Neuron       Date:  2016-06-01       Impact factor: 17.173

6.  Identification of novel liver X receptor activators by structure-based modeling.

Authors:  Susanne von Grafenstein; Judit Mihaly-Bison; Gerhard Wolber; Valery N Bochkov; Klaus R Liedl; Daniela Schuster
Journal:  J Chem Inf Model       Date:  2012-04-20       Impact factor: 4.956

Review 7.  Ligands of Therapeutic Utility for the Liver X Receptors.

Authors:  Rajesh Komati; Dominick Spadoni; Shilong Zheng; Jayalakshmi Sridhar; Kevin E Riley; Guangdi Wang
Journal:  Molecules       Date:  2017-01-05       Impact factor: 4.411

8.  Cross-Talk between PPARs and the Partners of RXR: A Molecular Perspective.

Authors:  Lap Shu Alan Chan; Richard A Wells
Journal:  PPAR Res       Date:  2009-12-20       Impact factor: 4.964

9.  Ligand specificity and evolution of liver X receptors.

Authors:  Erica J Reschly; Ni Ai; William J Welsh; Sean Ekins; Lee R Hagey; Matthew D Krasowski
Journal:  J Steroid Biochem Mol Biol       Date:  2008-03-10       Impact factor: 4.292

10.  Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment.

Authors:  Caroline A Phelan; Joseph M Weaver; David J Steger; Shree Joshi; Jeffrey T Maslany; Jon L Collins; William J Zuercher; Timothy M Willson; Max Walker; Michael Jaye; Mitchell A Lazar
Journal:  Mol Endocrinol       Date:  2008-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.